AU2006210817B2 - Novel adenosine A3 receptor modulators - Google Patents

Novel adenosine A3 receptor modulators Download PDF

Info

Publication number
AU2006210817B2
AU2006210817B2 AU2006210817A AU2006210817A AU2006210817B2 AU 2006210817 B2 AU2006210817 B2 AU 2006210817B2 AU 2006210817 A AU2006210817 A AU 2006210817A AU 2006210817 A AU2006210817 A AU 2006210817A AU 2006210817 B2 AU2006210817 B2 AU 2006210817B2
Authority
AU
Australia
Prior art keywords
dione
propyl
benzyl
substituted
purine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006210817A
Other languages
English (en)
Other versions
AU2006210817A2 (en
AU2006210817A1 (en
Inventor
Pier Baraldi
Pier Andrea Borea
Delia Preti
Mojgan Aghazadeh Tabrizi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
King Pharmaceuticals Research and Development Inc
Original Assignee
King Pharmaceuticals Research and Development Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by King Pharmaceuticals Research and Development Inc filed Critical King Pharmaceuticals Research and Development Inc
Publication of AU2006210817A2 publication Critical patent/AU2006210817A2/en
Publication of AU2006210817A1 publication Critical patent/AU2006210817A1/en
Application granted granted Critical
Publication of AU2006210817B2 publication Critical patent/AU2006210817B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2006210817A 2005-02-02 2006-02-01 Novel adenosine A3 receptor modulators Ceased AU2006210817B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US64972605P 2005-02-02 2005-02-02
US60/649,726 2005-02-02
US11/344,295 2006-01-31
US11/344,295 US7435740B2 (en) 2005-02-02 2006-01-31 Adenosine A3 receptor modulators
PCT/US2006/003477 WO2006083916A2 (en) 2005-02-02 2006-02-01 Novel adenosine a3 receptor modulators

Publications (3)

Publication Number Publication Date
AU2006210817A2 AU2006210817A2 (en) 2006-08-10
AU2006210817A1 AU2006210817A1 (en) 2006-08-10
AU2006210817B2 true AU2006210817B2 (en) 2010-12-23

Family

ID=36777854

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006210817A Ceased AU2006210817B2 (en) 2005-02-02 2006-02-01 Novel adenosine A3 receptor modulators

Country Status (11)

Country Link
US (1) US7435740B2 (enExample)
EP (1) EP1845993A4 (enExample)
JP (1) JP2008538099A (enExample)
KR (1) KR20070100331A (enExample)
AU (1) AU2006210817B2 (enExample)
BR (1) BRPI0606750A2 (enExample)
CA (1) CA2596612A1 (enExample)
IL (1) IL184532A0 (enExample)
MX (1) MX2007008501A (enExample)
NZ (1) NZ556649A (enExample)
WO (1) WO2006083916A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
WO2009092602A2 (en) * 2008-01-24 2009-07-30 Universität Zürich Anti-angiogenic compounds
US20110190324A1 (en) * 2008-07-16 2011-08-04 Edward Leung Methods of treating atherosclerosis
EP2456419B1 (en) 2009-07-21 2016-11-23 Oradin Pharmaceutical Ltd. A3 adenosine receptor ligands for modulation of pigmentation

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586429B2 (en) * 2000-11-29 2003-07-01 Cell Therapeutics, Inc. Tricyclic fused xanthine compounds and their uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DRABCZYNSKA, et al. "Tricyclic oxazolo[2,3-f]purinediones: potency as adenosine receptor ligands and anticonvulsants" BIOORGANIC & MEDICINAL CHEMISTRY, 2004. Vol. 12(18): 4895-4908 *
PRIEGO, E et al. "Pyrido(2,1-f)purine-2,4-dione derivatives as a novel class of highly potent human A3 adenosine receptor antagonists" JOURNAL OF MEDICINAL CHEMISTRY, 2002. Vol. 45(16): 3337-3344 *

Also Published As

Publication number Publication date
US7435740B2 (en) 2008-10-14
NZ556649A (en) 2010-03-26
AU2006210817A2 (en) 2006-08-10
KR20070100331A (ko) 2007-10-10
IL184532A0 (en) 2007-10-31
WO2006083916A2 (en) 2006-08-10
AU2006210817A1 (en) 2006-08-10
JP2008538099A (ja) 2008-10-09
WO2006083916A3 (en) 2007-12-21
EP1845993A4 (en) 2009-03-11
BRPI0606750A2 (pt) 2009-07-14
CA2596612A1 (en) 2006-08-10
US20060178385A1 (en) 2006-08-10
EP1845993A2 (en) 2007-10-24
MX2007008501A (es) 2007-09-14

Similar Documents

Publication Publication Date Title
JP5084725B2 (ja) 有機化合物
JP5816678B2 (ja) ＰＩ３Ｋδ阻害剤としての縮合誘導体
EP2516441B1 (en) Pteridinones as inhibitors of polo-like kinase
DK2057156T3 (en) 2-METHYLMORPHOLINPYRIDO, PYRAZO AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS
EP2038285B1 (en) Adenosine a2a receptor antagonists
RS54702B1 (sr) Pirazolohinolinski derivati kao inhibitori pde9
CA2819625A1 (en) 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
JP2008531537A (ja) 化合物
JP2016537366A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体
JPH0749429B2 (ja) アザインデン、その製法、これを含有する高血圧及びうつ血性心臓疾患の治療剤及び中間体
JPS60231661A (ja) 抗ビールス性化合物
CN116425756B (zh) 腺苷受体拮抗剂化合物及其应用
JP2013518904A (ja) タンパク質キナーゼ阻害剤としての化合物および組成物
WO2015069441A1 (en) Pyrazolo-, imidazolo- and pyrrolo-pyridine or -pyrimidine derivatives as inhibitors o brutons kinase (btk)
JP7777596B2 (ja) Ｃｄ３８阻害剤としてのキノリン及びアザキノリン
AU2006210817B2 (en) Novel adenosine A3 receptor modulators
JP2020528922A (ja) アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体
Ghorab et al. Design and synthesis of novel thiophenes bearing biologically active aniline, aminopyridine, benzylamine, nicotinamide, pyrimidine and triazolopyrimidine moieties searching for cytotoxic agents
CN101155785A (zh) 新型腺苷a3受体调节剂
CN101268072A (zh) Dna-pk抑制剂
NZ742891A (en) 4-amino-2-(1h-pyrazolo[3,4-b]pyridin-3-yl)-6-oxo-6,7-dihydro-5h-pyrrolo[2,3-d]pyrimidine derivatives and the respective (1h-indazol-3-yl) derivatives as cgmp modulators for treating cardiovascular diseases
NZ622594B2 (en) Pyrazoloquinoline derivative

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 13 AUG 2007

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired